What are the precautions for Dramani/Delba?

Delamanid is an innovative oral medicine for multidrug-resistant tuberculosis (MDR-TB). Although it has shown good efficacy in the treatment of multi-drug-resistant tuberculosis, there are certain risks and precautions during use, which require high attention from patients and clinicians. This article will analyze in detail the precautions for the use of delamanid from multiple dimensions to help patients use it safely and standardizedly.

1. Medication cycle and clinical indication restrictions

The clinical study of delamanid is mainly aimed at patients with multi-drug-resistant tuberculosis, and the treatment cycle is 24 weeks (6 months). There are currently no safety and efficacy data on continuous use for more than 24 weeks. Therefore, it is not recommended to use it beyond the recommended period.

In addition, this product does not have clinical data to support the following indications: extrapulmonary tuberculosis, including infections of the central nervous system, bones, etc.; infections caused by non-tuberculous mycobacteria; latent infections with Mycobacterium tuberculosis; and combination treatment regimens for drug-sensitive Mycobacterium tuberculosis.

2. Risk of drug resistance

Delamanid must be used in combination treatment regimens for MDR-TB to prevent the development of drug resistance. Single drug use may lead to drug resistance of tuberculosis bacteria, thereby reducing the effectiveness of treatment. Therefore, patients must strictly follow medical instructions when using this product and combine it with other anti-tuberculosis drugs as prescribed.

3. QT interval prolongation and cardiac monitoring

Delamanid may causeQT interval prolongation, which is one of the most important drug safety concerns in clinical practice. In order to ensure the safety of medication, it is recommended to take the following measures:

An electrocardiogram (ECG) needs to be checked before medication and monitored once a month during the entire treatment period; if QTcF>500ms before the first dose or during treatment, the medication should be stopped or not started; if the QTc interval continues to exceed 450/470ms during treatment, the frequency of ECG monitoring should be increased; serum electrolyte levels, especially potassium, calcium, and magnesium, need to be checked before treatment, and any abnormalities need to be corrected.

4. Use with caution in high-risk patients

Delamanid should be used with caution or only after weighing the potential benefits and risks in the following patients: patients with known congenital QT prolongation or QT>500ms; patients with a history of symptomatic arrhythmias or clinically relevant cardiac arrest Brady; have heart disease that may induce arrhythmias, such as severe hypertension, left ventricular hypertrophy, congestive heart failure with reduced ejection fraction; patients with electrolyte disorders, especially hypokalemia, hypocalcemia, or hypomagnesemia; and are taking drugs known to prolong the QTc interval.

5. Attention to hypoalbuminemia

If patients have hypoalbuminemia (albumin<2.8g/dL), the use of delamanid will significantly increase the risk of QTc interval prolongation, so this drug is contraindicated. Clinically, serum albumin levels should be assessed before medication to ensure safety.

6. Interactions with CYP3A inhibitors

The main metabolite of delamanidWhen DM-6705 is used in combination with a strong CYP3A inhibitor, its plasma concentration may increase by approximately 30%, further increasing the risk of QT interval prolongation. If combined use is necessary, high-frequency electrocardiogram monitoring should be performed throughout the process, and the dosage should be adjusted under the guidance of a physician.

7. Effects on driving and operating machinery

There are no studies that have systematically evaluated the effects of delamanid on the ability to drive or operate machinery. Patients are advised to avoid driving and operating dangerous machinery during treatment to avoid accidents.

8. Discontinuation and dose adjustment

If serious adverse reactions occur orQT interval is significantly prolonged, the drug should be discontinued immediately. After the symptoms are relieved, the dose can be adjusted and resumed under the guidance of a doctor; in severe cases, permanent drug discontinuation may be required. Strict compliance with medical instructions and regular follow-up visits are the keys to ensuring the safety and effectiveness of treatment.

Reference: https://go.drugbank.com/drugs/DB11637